GYNECOL ONCOL ：抗糖尿病药物与子宫内膜癌风险无关

　　瑞士一项研究表明，使用二甲双胍和其他抗糖尿病药物与子宫内膜癌患病风险无关。该研究论文3月20日在线发表于《妇科肿瘤学》（Gynecol Oncol）杂志。

　　该研究是一项病例对照研究，利用英国全科医学研究数据库（GPRD）探索了二甲双胍和其他抗糖尿病药物与子宫内膜癌风险的关联。研究对象为偶发性子宫内膜癌患者和与之匹配的对照者。

　　结果，研究共纳入2554例子宫内膜癌患者和15324名对照者。与从未使用二甲双胍相比，曾经使用二甲双胍与子宫内膜癌风险改变无关。基于抗糖尿病药物暴露时间的分层分析显示，长期使用二甲双胍、磺脲类药物、噻唑烷二酮类药物或胰岛素均与子宫内膜癌风险无关。

与子宫内膜癌相关的拓展阅读：

• 宫腔镜诊断子宫内膜癌优于分段诊刮
• Nat Genet：外显子测序显示数种体细胞突变可导致子宫内膜癌
• AJE：女性30岁后生育会降低子宫内膜癌风险
• PLoS ONE：miR-205可能是子宫内膜癌预后标记物
• 子宫内膜癌：两药联合 vs 三药联合化疗
更多信息请点击：有关子宫内膜癌更多资讯

Metformin and the risk of endometrial cancer: A case–control analysis

Objective

To explore the risk of endometrial cancer in relation to metformin and other antidiabetic drugs.

Methods

We conducted a case–control analysis to explore the association between use of metformin and other antidiabetic drugs and the risk of endometrial cancer using the UK-based General Practice Research Database (GPRD). Cases were women with an incident diagnosis of endometrial cancer, and up to 6 controls per case were matched in age, sex, calendar time, general practice, and number of years of active history in the GPRD prior to the index date. Odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated and results were adjusted by multivariate logistic regression analyses for BMI, smoking, a recorded diagnosis of diabetes mellitus, and diabetes duration.

Results

A total of 2554 cases with incident endometrial cancer and 15,324 matched controls were identified. Ever use of metformin compared to never use of metformin was not associated with an altered risk of endometrial cancer (adj. OR 0.86, 95% CI 0.63–1.18). Stratified by exposure duration, neither long-term (≥ 25 prescriptions) use of metformin (adj. OR 0.79, 95% CI 0.54–1.17), nor long-term use of sulfonylureas (adj. OR 0.96, 95% CI 0.65–1.44), thiazolidinediones (≥ 15 prescriptions; adj. OR 1.22, 95% CI 0.67–2.21), or insulin (adj. OR 1.05 (0.79–1.82) was associated with the risk of endometrial cancer.

Conclusion

Use of metformin and other antidiabetic drugs were not associated with an altered risk of endometrial cancer.